Full index of posts »
StockTalks
-
CENTRAL THESIS FOR AN INVESTMENT IN KOOL: CORD BLOOD AND ADULT STEM CELL INDUSTRY SIMPLY CANNOT CONTINUE TO EXIST WITHOUT KOOL'S PRODUCTS May 4, 2011
-
KOOL: Cord blood storage is fast becoming something offered as an option to all expecting mothers throughout the world May 4, 2011
-
KOOL: Every day, new usages for adult stem cells are being discovered or established; the potential uses are unknowable at this point May 4, 2011
Latest Comments
-
yellowtailcheek on Central Thesis for an Investment in Thermogenesis Corporation the missing part... chinese approval of AXP sho...
-
yellowtailcheek on Central Thesis for an Investment in Thermogenesis Corporation kool management really needs to get up to speed...
-
getuptopeak on Central Thesis for an Investment in Thermogenesis Corporation It's getting riskier everyday to stay on the si...
-
yellowtailcheek on Central Thesis for an Investment in Thermogenesis Corporation i bot 50,000 shares at $2.03. i don't believe t...
Most Commented
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.












View KOOLANDTHEGANG's Instablogs on:
Central Thesis for an Investment in Thermogenesis Corporation
The market is completely snoozing on Thermogenesis Corp. (KOOL) -- but that's OK -- I continue to buy more.
In my view, here are the primary investment considerations:
(A) High Margins, Higher Margin Projections
(B) Cord Blood Becoming the "Go-To" Source for Adult Stem Cells and Adult Stem Cells Becoming More and More Indispensable
(C) Has the Worldwide Distribution Network Befitting a Billion Dollar Company
(D) Even Putting Aside AXP and BioArchive, Tremendous Growth Opportunities Abound
(E) Last But Not Least: CLEAN BALANCE SHEET AND INSANELY CHEAP VALUATION
It boggles my mind that this company is trading at a lower valuation than at any time in its 20 year history, and yet has the all the trappings of a future billion dollar company. I hope to be able to say one day that I was lucky enough to buy this stock before it becomes the CSCO or MSFT of the stem-cell industry.
Disclosure: I am long KOOL.